Business Context and Reporting Period
This Form 6-K filing by Clearmind Medicine Inc. covers the month of September 2024, with the report dated September 26, 2024. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance report and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the appointment of a new director to the Board of Directors.
- New Director: Hila Kiron-Revach was appointed effective September 26, 2024.
- Background: Ms. Kiron-Revach brings experience from serving on the boards of Rail Vision Ltd. (since 2024), Geffen Biomed Ltd. (since 2014), and Zmiha Investment House Ltd. (since 2021).
- Professional History: She previously served as a senior professional advisor to Israeli government ministers (2015–2021), CEO of Hamil 38 (2012–2015), and as a licensed attorney.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document focuses solely on the board appointment and its incorporation by reference into existing Registration Statements on Form F-3.
Investor Verification Checklist
- Verify the effective date of Hila Kiron-Revach's board appointment (September 26, 2024).
- Review Ms. Kiron-Revach's prior board service at Rail Vision Ltd. and Geffen Biomed Ltd. for potential conflicts of interest or strategic alignment.
- Confirm the incorporation of this Form 6-K into the Company's active Form F-3 Registration Statements (File Nos. 333-275991, 333-270859, 333-273293).
- Note that no financial performance data is included in this specific filing; refer to recent Form 20-F or quarterly reports for financial metrics.